Failure of Treatment with First‐Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V | Zendy

Monique Nijhuis | Zendy; Annemarie M. J. Wensing | Zendy; Wouter F.W. Bierman | Zendy; Dorien de Jong | Zendy; Ron M. Kagan | Zendy; Axel Fun | Zendy; C. A. J. J. Jaspers | Zendy; Karin A. M. Schurink | Zendy; Michael A. van Agtmael | Zendy; Charles A. Boucher | Zendy

Open Access

Failure of Treatment with First‐Line Lopinavir Boosted with Ritonavir Can Be Explained by Novel Resistance Pathways with Protease Mutation 76V

Author(s) -

Monique Nijhuis,

Annemarie M. J. Wensing,

Wouter F.W. Bierman,

Dorien de Jong,

Ron M. Kagan,

Axel Fun,

C. A. J. J. Jaspers,

Karin A. M. Schurink,

Michael A. van Agtmael,

Charles A. Boucher

Publication year - 2009

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/605329

Subject(s) - lopinavir , ritonavir , protease , lopinavir/ritonavir , virology , protease inhibitor (pharmacology) , biology , drug resistance , medicine , virus , viral load , genetics , antiretroviral therapy , enzyme , biochemistry

Virological failure of first-line antiretroviral therapy based on lopinavir boosted with ritonavir (lopinavir/r) has rarely been associated with resistance in protease. We identified a new genotypic resistance pathway in 3 patients who experienced failure of first-line lopinavir/r treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research